HBK Investments’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
– Sell
-2,004,042
Closed -$96.2M – 559
2020
Q1
$96.2M Buy
2,004,042
+1,922,677
+2,363% +$89.4M 4.03% 10
2019
Q4
$3.82M Buy
+81,365
New +$3.6M 0.04% 333

Other funds holding RARX

HBK Investments's RARX Position: Q2 2020 in Review

HBK Investments sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 2,004,042 shares — an estimated $96.2M sold.

HBK Investments first reported a position in RARX in Q4 2019 and held it in 2 quarters. The position peaked at $96.2M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

  • HBK Investments reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • HBK Investments sold 2,004,042 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $96.2M.
  • HBK Investments first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • HBK Investments's Ra Pharmaceuticals, Inc. Common Stock position peaked at $96.2M in Q1 2020.
  • 1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on HBK Investments's 13F filing for Q2 2020, filed 14 Aug 2020.